ISPOR 2019

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 24th annual conference from May 18-22, 2019, in New Orleans, Louisiana, with a focus on developments in health economics and outcomes research. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
August 22, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
August 10, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
July 29, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.
July 23, 2019
Eleanor M. Perfetto, PhD, MS, senior vice president of Strategic Initiatives for the National Health Council, discusses potential strategies for increasing transparency in value assessment and where education fits into the mix.
July 16, 2019
With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.
July 14, 2019
If you set social benefits equal to social costs, you will be able to maximize the well-being of a population, and that's what value assessment allows for, explained Devin Incerti, PhD, lead economist, Innovation and Value Initiative.
June 23, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the need for standardizing the use of real-world evidence for measuring endpoints in clinical practice.
June 03, 2019
Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses the value of multi-criteria decision analysis (MCDA) in value assessment, as well as lessons learned from using MCDA in other industries.
May 27, 2019
A computer simulated cost-effectiveness model of fremanezumab for migraine found that it was cost effective versus no treatment. Researchers presented a poster about its cost-effectiveness for the prevention of chronic and episodic migraine at ISPOR 2019.
May 23, 2019
The upfront prices of potentially curative therapies are terrifying to commercial payers and government payers alike. A panel on the last day of ISPOR 2019 discussed these issues in a session called, “Is Affordability Driving a Need to Revolutionize Drug Pricing?”
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.